Ribociclib plus letrozole for first-line treatment of HR+, HER2-ABC: efficacy, safety, and pharmacokinetics

Affiliation auteurs!!!! Error affiliation !!!!
TitreRibociclib plus letrozole for first-line treatment of HR+, HER2-ABC: efficacy, safety, and pharmacokinetics
Type de publicationJournal Article
Year of Publication2016
AuteursAndre F., Stemmer S.M, Hortobagyi G.N, Burris H.A, Paluch-Shimon S., Campone M., Villanueva C., Chan A., Wist E., Marschner N., Bachelot T., Blau S., Janni W., Verma S., Conte P., Dhuria S., Yang S., Stegert M., Germa C., Arteaga C.L
JournalEUROPEAN JOURNAL OF CANCER
Volume69
PaginationS7
Date PublishedDEC
Type of ArticleMeeting Abstract
ISSN0959-8049
DOI10.1016/S0959-8049(16)32619-3